New drug cocktail aims to shrink Hard-to-Treat neuroendocrine tumors

NCT ID NCT06157827

Recruiting now Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called LBL-024 combined with standard chemotherapy (etoposide plus platinum) as a first treatment for people with advanced neuroendocrine carcinoma. About 178 adults aged 18-75 will take part to see if the combination is safe and helps shrink tumors. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LBL-024 combined with etoposide and platinum chemotherapy
What this could lead to: If successful, this could offer a new first-line treatment option for advanced neuroendocrine carcinoma, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NEUROENDOCRINE CARCINOMA

Contacts and locations

Locations

Anhui Cancer Hospital
RECRUITING

Hefei, Anhui, 230031, China
Anhui Provincial Hospital
RECRUITING

Hefei, Anhui, 230001, China
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 100070, China
Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, 530021, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, 430079, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, 110801, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250063, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
Shanxi Cancer hospital
RECRUITING

Taiyuan, Shanxi, 030013, China
Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310016, China
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
RECRUITING

Guangzhou, Guangdong, 510080, China
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING

Luoyang, Henan, 471003, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610044, China
Xiangyang Central Hospital
RECRUITING

Xiangyang, Hubei, 441000, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.